Germline mutations in RUNX1 result in autosomal dominant familial platelet disorder with associated myeloid malignancy (FPDMM). To characterize the hematopathologic features associated with a germline RUNX1 mutation, we reviewed a total of 42 bone marrow aspirates from 14 FPDMM patients, including 24 cases with no cytogenetic clonal abnormalities, and 18 with clonal karyotypes or leukemia. We found that all aspirate smears had ≥10% atypical megakaryocytes, predominantly characterized by small forms with hypolobated and eccentric nuclei, and forms with high nuclear-to-cytoplasmic ratios. Core biopsies showed variable cellularity and variable numbers of megakaryocytes with similar features to those in the aspirates. Granulocytic and/or erythroid dysplasia (≥10% cells per lineage) were present infrequently. Megakaryocytes with separate nuclear lobes were increased in patients with myelodysplastic syndrome (MDS) and acute leukemia. Comparison to an immune thrombocytopenic purpura cohort confirms increased megakaryocytes with hypolobated eccentric nuclei in FPDMM patients. As such, patients with FPDMM often have atypical megakaryocytes with small hypolobated and eccentric nuclei even in the absence of clonal cytogenetic abnormalities; these findings are related to the underlying RUNX1 germline mutation and not diagnostic of MDS. Isolated megakaryocytic dysplasia in patients with unexplained thrombocytopenia should raise the possibility of an underlying germline RUNX1 mutation.
ChurpekJEPyrtelKKanchiKLet al.Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood2015; 126: 2484–2490.
ZhangMYKeelSBWalshTet al.Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica2015; 100: 42–48.
4.
PetersonLCBloomfieldCDNiemeyerCMet al., Myeloid neoplasms with germline predisposition. In: SwerdlowSHCampoEHarrisNLet al.(eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France: International Agency for Research on Cancer, 2017, pp. 122–128.
5.
GreenbergPLStoneRMAl-KaliAet al.Myelodysplastic syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw2017; 15: 60–87.
6.
BabushokDVBesslerM. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?. Best Pract Res Clin Haematol2015; 28: 55–68.
7.
GodleyLAShimamuraA. Genetic predisposition to hematologic malignancies: management and surveillance. Blood2017; 130: 424–432.
8.
MiyoshiHOhiraMShimizuKet al.Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res1995; 23: 2762–2769.
9.
WangSWangQCruteBEet al.Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol1993; 13: 3324–3339.
10.
HuangGShigesadaKItoKet al.Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J2001; 20: 723–733.
11.
GuTLGoetzTLGravesBJet al.Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1). Mol Cell Biol2000; 20: 91–103.
12.
KannoTKannoYChenLFet al.Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit. Mol Cell Biol1998; 18: 2444–2454.
13.
JavedAGuoBHiebertSet al.Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene transcription. J Cell Sci2000; 113(Pt 12): 2221–2231.
14.
KuvardinaONHerglotzJKolodziejSet al.RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood2015; 125: 3570–3579.
15.
LutterbachBWestendorfJJLinggiBet al.A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem2000; 275: 651–656.
16.
YuMMazorTHuangHet al.Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell2012; 45: 330–343.
17.
LorsbachRBMooreJAngSOet al.Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood2004; 103: 2522–2529.
18.
NorthTEStacyTMathenyCJet al.Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating myeloid and lymphoid cells, but not in maturing erythroid cells. Stem Cells2004; 22: 158–168.
19.
ElagibKERackeFKMogassMet al.RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood2003; 101: 4333–4341.
20.
SongWJSullivanMGLegareRDet al.Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet1999; 23: 166–175.
21.
DowtonSBBeardsleyDJamisonDet al.Studies of a familial platelet disorder. Blood1985; 65: 557–563.
22.
Ouchi-UchiyamaMSasaharaYKikuchiAet al.Analyses of genetic and clinical parameters for screening patients with inherited thrombocytopenia with small or normal-sized platelets. Pediatr Blood Cancer2015; 62: 2082–2088.
23.
GlembotskyACBluteauDEspasandinYRet al.Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets. J Thromb Haemost2014; 12: 761–772.
24.
StockleyJMorganNVBemDet al.Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood2013; 122: 4090–4093.
25.
GanlyPWalkerLCMorrisCM. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma2004; 45: 1–10.
26.
Antony-DebreIManchevVTBalaynNet al.Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood2015; 125: 930–940.
27.
Latger-CannardVPhilippeCBouquetAet al.Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J Rare Dis2016; 11: 49.
28.
MichaudJWuFOsatoMet al.In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood2002; 99: 1364–1372.
29.
Della PortaMGTravaglinoEBoveriEet al.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia2015; 29: 66–75.
30.
FengGGaleRPCuiWet al.A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol2015; 5: 12.
31.
GoasguenJEBennettJMBainBJet al.Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: difficulties in the assessment of dysplasia. Leuk Res2016; 45: 75–81.
32.
HasserjianROraziABrunningRDet al., Myelodysplastic syndromes: overview. In: SwerdlowSHCampoEHarrisNLet al.(eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France: International Agency for Research on Cancer, 2017, pp. 98–106.
33.
MatsudaAGermingUJinnaiIet al.Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia2007; 21: 678–686.
34.
GoasguenJEBennettJMBainBJet al.Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. Br J Haematol2018; 182: 526–533.
35.
GoasguenJEBennettJMBainBJet al.Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res2014; 38: 447–453.
36.
FriebertSEShepardsonLBShurinSBet al.Pediatric bone marrow cellularity: are we expecting too much?. J Pediatr Hematol Oncol1998; 20: 439–443.
37.
ProytchevaM. Bone marrow evaluation for pediatric patients. Int J Lab Hematol2013; 35: 283–289.
38.
SakuraiMKunimotoHWatanabeNet al.Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia2014; 28: 2344–2354.
39.
SchmitJMTurnerDJHromasRAet al.Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep2015; 4: 24–27.
40.
WalkerLCStevensJCampbellHet al.A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. Br J Haematol2002; 117: 878–881.
41.
Latger-CannardVPhilippeCJonveauxPet al.Dysmegakaryopoiesis, a clue for an early diagnosis of familial platelet disorder with propensity to acute myeloid leukemia in case of unexplained inherited thrombocytopenia associated with normal-sized platelets. J Pediatr Hematol Oncol2011; 33: e264–e266.
42.
HellerPGGlembotskyACGandhiMJet al.Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood2005; 105: 4664–4670.
43.
Kanagal-ShamannaRLoghaviSDiNardoCDet al.Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica2017; 102: 1661–1670.
44.
OkCYLeventakiVWangSAet al.Detection of an abnormal myeloid clone by flow cytometry in familial platelet disorder with propensity to myeloid malignancy. Am J Clin Pathol2016; 145: 271–276.
45.
TsangHCBusselJBMathewSet al.Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. Mod Pathol2017; 30: 486–498.
46.
BluteauDGlembotskyACRaimbaultAet al.Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood2012; 120: 2708–2718.
47.
IizukaHKagoyaYKataokaKet al.Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Exp Hematol2015; 43: 849–857.
48.
IchikawaMAsaiTSaitoTet al.AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med2004; 10: 299–304.
49.
ThieleJFischerR. Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview. Virchows Arch A Pathol Anat Histopathol1991; 418: 87–97.
50.
ThieleJvon AmmersEWagnerSet al.Megakaryocytopoiesis in idiopathic thrombocytopenic purpura: a morphometric and immunohistochemical study on bone marrow biopsies with special emphasis on precursor cells. Hematol Pathol1991; 5: 75–82.
51.
AqilBPuniaJNCurryCVet al.Are micromegakaryocytes specific for refractory cytopenia of childhood (RCC)? A study of 38 pediatric patients with thrombocytopenia unrelated to RCC. Leuk Res2016; 47: 84–87.
52.
DekaLGuptaSGuptaRet al.Morphometric evaluation of megakaryocytes in bone marrow aspirates of immune-mediated thrombocytopenic purpura. Platelets2013; 24: 113–117.
53.
ManganJKSpeckNA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog2011; 16: 77–91.
54.
Antony-DebreIDuployezNBucciMet al.Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia2016; 30: 999–1002.
55.
HaslamKLangabeerSEHayatAet al.Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia. Br J Haematol2016; 175: 161–163.
56.
PreudhommeCRennevilleABourdonVet al.High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood2009; 113: 5583–5587.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
